Millipore Corporation (NYSE:MIL), a provider of technologies, tools and services for the global life science industry, is supporting an executive order signed by President Barack Obama at the White House today, which rescinds limits on federal funding of stem cell research. Millipore is a leading provider of stem cell products to the biomedical research community.

"President Obama's executive order opens a significant new chapter in stem cell research," said Millipore President, Chairman and CEO Martin Madaus. "The potential to treat and even cure disease is enormous. This executive order will broaden and expand stem cell based life science research that holds the promise to develop therapies for today's incurable diseases. Millipore is deeply committed to enabling the advancement of ethical stem cell research and being a scientific partner in the stem cell research community."

Millipore is a leading supplier of cell lines, specialty media and sample preparation devices for stem cell research. Recent announcements include:

- An expansion of the company's industry-leading line of reporter stem cells to include ReNcell™ immortalized neural progenitor cells. Reporter cell lines include a molecular marker to track cell differentiation.

- Introduction of new FastTrap® Virus Purification kits, which simplifies the purification of vectors that can be used to reprogram differentiated cells into an induced pluripotent state.

- A collaboration with the Burnham Institute for Medical Research to broadcast the Southern California Stem Cell Consortium's monthly meeting as a free online webinar.

- Launch of a stem cell learning center that provides open access to tools, protocols and scientific material for stem cell researchers worldwide: http://www.millipore.com/stemcell/stm/stemcell

In addition to its own team of scientists dedicated to stem cell research, Millipore has sponsored stem cell research and training programs at leading academic institutions around the world, including the Burnham Institute in San Diego, the Australian Stem Cell Center in Melbourne, the Harvard Stem Cell Institute and the Scripps Research Institute.

About Millipore

Millipore (NYSE: MIL) is a Life Science leader providing cutting-edge technologies, tools, and services for bioscience research and biopharmaceutical manufacturing. As a strategic partner, we collaborate with customers to confront the world's challenging human health issues. From research to development to production, our scientific expertise and innovative solutions help customers tackle their most complex problems and achieve their goals. Millipore Corporation is an S&P 500 company with more than 5,900 employees worldwide. For more information, visit http://www.millipore.com

Safe Harbor Statement

Certain of the matters discussed herein, as well as in future oral and written statements by management of Millipore Corporation that are forward-looking statements, are based on current management expectations that involve substantial risks and uncertainties which could cause actual results to differ materially from the results expressed in, or implied by, these forward-looking statements.

Potential risks and uncertainties that could affect Millipore's future results include, without limitation, failure to achieve design wins into our pharmaceutical and biotechnology customers' manufacturing design phase for a particular drug; delay, suspension or termination of a customer's volume production; fluctuations in the timing of customers' orders; lack of availability of raw materials or component products on a timely basis; regulatory delay in the approval of new therapeutics; limitations on cash flow for operations and investment due to debt service obligations; the inability to establish and maintain necessary product and process quality levels; reduced demand for cell culture products using bovine serum; the inability to realize the expected benefits of development, marketing, licensing and other alliances; competitive factors such as new membrane or chromatography technology; risks relating to our concentration of principal manufacturing operations; the inability to successfully integrate acquired businesses; the inability to utilize technology in current or planned products due to overriding rights by third parties; potential environmental liabilities; conditions in the economy in general and in the bioscience and bioprocess markets in particular; foreign exchange fluctuations; reduced private and government research funding; exposure to product liability claims; and difficulties inherent in transferring or outsourcing of manufacturing operations. Please refer to our filings with the SEC, including our most recent Annual Report on Form 10-K, for more information on these and other risks that could cause actual results to differ.

Millipore